Venetoclax to shrink HIV reservoir in people on stable ART
Treatments studied
Part of Infections clinical trials.
This Phase 1/2 study tests whether venetoclax can help reduce the “HIV reservoir,” which is a hidden group of HIV-infected cells, while you stay on your usual HIV treatment. It also looks at whether the drug helps these infected cells die off in a controlled, safe way.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed HIV-1 infection and are between 18 and 65 years old.
- You have been on combination HIV treatment (ART) for at least 2 years and have stayed on the same ART regimen for at least 4 weeks before screening.
- Your viral load on ART is very low: under 20 copies/mL at screening, and under 50 copies/mL for over 2 years (with allowances if levels briefly rose then returned to under 50).
- Your immune system is strong: CD4 count must be over 500 cells/µL at screening, and it has been over 500 at least twice in the past 24 months.
- You must be willing and able to keep taking ART the same way during the study and follow study visits and procedures; you must be able to give informed consent.
- You must be able to manage venetoclax-drug safety rules: no venetoclax-type “pro-apoptosis/BCL-2” drugs for cancer use, no certain strong interacting medicines (especially some anti-fungal/antibiotic/heart/anti-viral and liver-enzyme medicines), and no major liver, kidney, blood count, or serious heart problems. (Your study doctor will review your current meds and recent health.)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted pill called venetoclax for people whose hairy cell leukemia has returned after other treatments. It aims to see if venetoclax can help control the disease and improve blood counts.
This trial tests giving venetoclax to people with CLL who are already taking a BTK inhibitor and have stable disease. The goal is to see if adding venetoclax can help eliminate any remaining CLL cells.
This trial tests how well venetoclax (a targeted pill for CLL) works in people whose CLL has come back or hasn’t responded. It also closely tracks early changes in the CLL cells to better understand what happens during treatment.
This trial studies how well venetoclax combined with chemotherapy treats newly diagnosed or returning (relapsed) or hard-to-treat (refractory) acute myeloid leukemia (AML). It’s mainly for people who can’t use standard AML therapy well, or whose disease came back.
This Phase 1 trial studies whether a combination of venetoclax (ABT-199) and “purine analogues” can help adults with AML that has come back or didn’t respond to earlier treatment. It’s designed to test safety and early effectiveness in people who haven’t previously developed resistance to venetoclax.
This Phase 2 trial tests whether adding venetoclax to a chemotherapy plan works better for Philadelphia chromosome–negative acute lymphoblastic leukemia (ALL). It may help people achieve deeper remission by targeting leukemia cells in a different way than chemotherapy alone.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.